NEW YORK (GenomeWeb) – Researchers from Brigham and Women's Hospital and Adaptive Biotechnologies have demonstrated that a next-generation sequencing-based assay developed by Adaptive is better at diagnosing cutaneous T cell lymphoma than the standard PCR-based test, and that it can assess patients' response to therapy and identify disease recurrence.